Potent adenosine A1 and A2A receptors antagonists:: Recent developments

被引:41
|
作者
Yuzlenko, O. [1 ]
Kiec-Kononowicz, K. [1 ]
机构
[1] Jagiellonian Univ, Coll Med, Dept Technol & Biotechnol Drugs, PL-30688 Krakow, Poland
关键词
A(1) adenosine receptor antagonists; A(2A) adenosine receptor antagonists; xanthine derivatives; nitrogen (poly)heterocyclic compounds;
D O I
10.2174/092986706779026093
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review summarizes the current tendencies observed in the past 5 years in the development of A(1) and A(2A) adenosine receptor antagonists performed in various academia and industry. A(1) and A(2A) AR antagonists are as well xanthines as heteroaromatic derivatives and are most commonly 6:5 fused heteroatomic compounds. Among xanthine-based compounds, some common features could be pointed out. The recent A(1) AR ligands which show good biological profile, possess long alkyl chains in position 1 and 3 as well as bulky C(8)-substituent, while A(2A) AR antagonists with a high A(2A) AR affinity are C(8)-styryl substituted with N(1)-alkyl/alkynyl moiety or fused tricyclic xanthines possessing heteroatom(s) in the third cycle. The research in the field of heteroaromatic A(1) and A(2A) ARs antagonists impressively has a wide range. Ligands are as well non-fused monocyclic substituted compounds as fused bi- and tricyclic derivatives with the nitrogen, oxygen and sulfur heteroatoms. Most often, adenosine A(1) receptor non-xanthine antagonists are adenine-based, having substituted amino group and variable nitrogen atoms positions in the molecules. A(2A) AR ligands show good affinity when furanyl function, which is crucial for binding, is present in the fused bicyclic and tricyclic analogs. Moreover, tricyclic nitrogen containing antagonists in order to be active, frequently possess long-alkylphenyl moiety.
引用
收藏
页码:3609 / 3625
页数:17
相关论文
共 50 条
  • [1] Optimization of arylindenopyrimidines as potent adenosine A2A/A1 antagonists
    Shook, Brian C.
    Rassnick, Stefanie
    Chakravarty, Devraj
    Wallace, Nathaniel
    Ault, Mark
    Crooke, Jeffrey
    Barbay, J. Kent
    Wang, Aihua
    Leonard, Kristi
    Powell, Mark T.
    Alford, Vernon
    Hall, Daniel
    Rupert, Kenneth C.
    Heintzelman, Geoffrey R.
    Hansen, Kristen
    Bullington, James L.
    Scannevin, Robert H.
    Carroll, Karen
    Lampron, Lisa
    Westover, Lori
    Russell, Ronald
    Branum, Shawn
    Wells, Kenneth
    Damon, Sandra
    Youells, Scott
    Beauchamp, Derek
    Li, Xun
    Rhodes, Kenneth
    Jackson, Paul F.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2868 - 2871
  • [2] Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists
    Shook, Brian C.
    Rassnick, Stefanie
    Hall, Daniel
    Rupert, Kenneth C.
    Heintzelman, Geoffrey R.
    Hansen, Kristen
    Chakravarty, Devraj
    Bullington, James L.
    Scannevin, Robert H.
    Magliaro, Brian
    Westover, Lori
    Carroll, Karen
    Lampron, Lisa
    Russell, Ronald
    Branum, Shawn
    Wells, Kenneth
    Damon, Sandra
    Youells, Scott
    Li, Xun
    Osbourne, Mel
    Demarest, Keith
    Tang, Yuting
    Rhodes, Kenneth
    Jackson, Paul F.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2864 - 2867
  • [3] Evaluation of 2-benzylidene-1-tetralone derivatives as antagonists of A1 and A2A adenosine receptors
    Legoabe, Lesetja J.
    Van der Walt, Mietha M.
    Terre'Blanche, Gisella
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2018, 91 (01) : 234 - 244
  • [4] A1 adenosine receptors and their ligands:: overview and recent developments
    Müller, CE
    [J]. FARMACO, 2001, 56 (1-2): : 77 - 80
  • [5] MOLECULAR CHARACTERIZATION OF A1 AND A2A ADENOSINE RECEPTORS
    JACOBSON, KA
    VANGALEN, PJM
    JI, XD
    RAMKUMAR, V
    OLAH, ME
    STILES, GL
    [J]. DRUG DEVELOPMENT RESEARCH, 1993, 28 (03) : 226 - 231
  • [6] Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A2A receptors
    Fredholm, BB
    Lindström, K
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 380 (2-3) : 197 - 202
  • [7] Recent developments in the field of A2A and A3 adenosine receptor antagonists
    Baraldi, PG
    Tabrizi, MA
    Bovero, A
    Avitabile, B
    Preti, D
    Fruttarolo, F
    Romagnoli, R
    Varani, K
    Borea, PA
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (04) : 367 - 382
  • [8] 2-Aminopyrimidines as dual adenosine A1/A2A antagonists
    Robinson, Sarel J.
    Petzer, Jacobus P.
    Terre'Blanche, Gisella
    Petzer, Anel
    van der Walt, Mietha M.
    Bergh, Jacobus J.
    Lourens, Anna C. U.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 104 : 177 - 188
  • [9] Human brain imaging of Adenosine A1 and A2A receptors
    Mishina, Masahiro
    [J]. PURINERGIC SIGNALLING, 2014, 10 (04) : 744 - 745
  • [10] Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors
    Jamwal, Sumit
    Mittal, Ashish
    Kumar, Puneet
    Alhayani, Dana M.
    Al-Aboudi, Amal
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (26) : 2892 - 2905